Floatz logo

Therapeutic Asset Ratings

3,272 results matching 1 filter

91,583 assets · 7,906 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Fexagratinib
Lymphoma
National Cancer Institute (NCI)P2B (57)
Fexagratinib
Hematopoietic And Lymphoid Cell Neoplasm
National Cancer Institute (NCI)P2B (57)
Fexagratinib
Refractory Malignant Neoplasm
National Cancer Institute (NCI)P2B (57)
FILGRASTIM
Lymphoproliferative Syndrome
National Cancer Institute (NCI)P2B (57)
FLUDEOXYGLUCOSE
Mesothelioma
National Cancer Institute (NCI)P2B (57)
FLUOROURACILUM
Anal Canal Squamous Cell Carcinoma
National Cancer Institute (NCI)P2B (57)
Hydrocortisone
Acute Leukemia Of Ambiguous Lineage
National Cancer Institute (NCI)P2B (57)
IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER
Ovarian Serous Adenocarcinoma
National Cancer Institute (NCI)P2B (57)
IMMUNOTHERAPIC BIFUNCTIONAL FUSION PROTEIN COMPRISED OF A FULLY HUMAN IGG1 MONOCLONAL ANTIBODY (AVELUMAB) AGAINST HUMAN PROGRAMMED DEATH-LIGAND 1 (PD-L1) FUSED TO THE SOLUBLE EXTRACELLULAR DOMAIN OF TRANSFORMING GROWTH FACTOR-.BETA. (TGF-.BETA.) RECEPTOR II, WHICH ACTS AS A TGF-.BETA. TRAP
Oropharyngeal Carcinoma
National Cancer Institute (NCI)P2B (57)
Ipilimumab
Malignant Glioma
National Cancer Institute (NCI)P2B (57)
MELPHALAN
Acute Myeloid Leukemia With Multilineage Dysplasia
National Cancer Institute (NCI)P2B (57)
Minnelide
Pancreatic Adenosquamous Carcinoma
National Cancer Institute (NCI)P2B (57)
mk-2206
Prostate Cancer
National Cancer Institute (NCI)P2B (57)
Nilotinib
Appendix Cancer
National Cancer Institute (NCI)P2B (57)
Nilotinib
Appendiceal Neoplasm
National Cancer Institute (NCI)P2B (57)
Nilotinib
Female Reproductive Organ Cancer
National Cancer Institute (NCI)P2B (57)
Nilotinib
Female Reproductive System Neoplasm
National Cancer Institute (NCI)P2B (57)
Nilotinib
Peritoneal Carcinomatosis
National Cancer Institute (NCI)P2B (57)
Nilotinib
Peritoneal Neoplasm
National Cancer Institute (NCI)P2B (57)
Nivolumab
Gallbladder Carcinoma
National Cancer Institute (NCI)P2B (57)
NOGITECAN
Myelodysplastic/Myeloproliferative Neoplasm
National Cancer Institute (NCI)P2B (57)
Olaparib
Langerhans Cell Histiocytosis
National Cancer Institute (NCI)P2B (57)
Olaparib
Malignant Germ Cell Tumor
National Cancer Institute (NCI)P2B (57)
Olaparib
Rhabdomyosarcoma
National Cancer Institute (NCI)P2B (57)
Olaparib
Hepatoblastoma
National Cancer Institute (NCI)P2B (57)
Showing 801 to 825 of 3,272 assets
PreviousPage 33 of 131Next